Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation as a sponsor at the Pharmaceutical and Bioscience Society (PBSS) San Francisco Antibody Drug Conjugate (ADC) workshop being held Wednesday September 12, 2018 at 8:45 a.m. at the SF Bay Area: Foster City Crowne Plaza in San Francisco, CA.
Applied BioMath employs a rigorous fit-for-purpose model development process, referred to as Model-Aided Drug Invention (MADI), which aims to quantitatively integrate knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Applied BioMath has vast experience applying MADI to support ADC research and development. For example, MADI allows the computational exploration of numerous scenarios, such as the analysis of drug-to-antibody ratio (DAR) or overall design of the ADC, in a fraction of the time it would take to figure out experimentally.
"We are excited to participate in this workshop and discuss how computational approaches can help accelerate the field of ADCs," said John Burke, PhD, Co-Founder, President and CEO, Applied BioMath. "MADI helps streamline the development of many types of therapeutics, but it is increasingly valuable in the design of ADCs given their multivariate complexity."
Applied BioMath previously aired a webinar on exploring ADC pharmacokinetics using QSP modeling strategies. The webinar demonstrated how QSP modeling approaches provide biological insights into the impact of drug-to-antibody (DAR) ratio and the resulting changes in molecular properties on overall pharmacokinetics and relative payload disposition as observed in preclinical studies. Applied BioMath first displayed this work at ADC World Congress, where they were awarded best poster.
For more information about Applied BioMath's upcoming events, visit www.appliedbiomath.com/news-resources/events.
About Applied BioMath
Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.
Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.
Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com